Highlights
- Oversees AGRI’s management and execution, guiding Target ALS efforts to generate and analyze data while fostering cross-functional collaboration to advance ALS research.
- Research expertise includes studying environmental and epidemiological factors in rare diseases, with a focus on health disparities and social determinants of health.
- Published in peer-reviewed journals on ALS epidemiology, rare cancer therapies, and public health equity initiatives.
- Frequent contributor to scientific conferences, presenting research findings at ALS MND and NEALS, as well as serving as an abstract reviewer and moderator for major public health forums.
Education
- Master of Public Health, University of North Carolina, Chapel Hill – 2020
- Bachelor of Science, Meredith College- 2016
Experience
- Associate Director of Project Management, Karyopharm Therapeutics, 2021-2023
- Oversee and manage Phase I-IV clinical trials focusing on rare cancer therapies.
- Clinical Research Consultant, 2019-2023
- Support biotechs and Clinical Research Organizations (CROS) in navigating clinical trial processes, offering strategic insights on protocol design, regulatory compliance, and overall study management.
- Clinical Trials Specialist, Duke Clinical Research Institute, 2018-2019
- Supported coordination and execution of longitudinal, natural history and real-world evidence (RWE) studies in cardiology and idiopathic pulmonary fibrosis (IPF) for the Outcomes Research Department.
Research Focus or Areas of Expertise
- Impact of environmental and epidemiological factors on rare diseases. Studying social determinants of health through the community- based, impact-oriented method to understand root causes of health disparities and inequities.
Publications & Contributions
- Theme 1 Epidemiology and Informatics. (2024). Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 25(sup1), 93–104.
https://doi.org/10.1080/21678421.2024.2403298 - Ali, H., Kishtagari, A., Maher, K., Mohan, S., Mazumder, A., Chamoun, K., Karasik, I., Sbar, E., Dugom, L., Tamir, S. and Wang, X., 2022. P1005: A PHASE 1, OPEN-LABEL, DOSE-ESCALATION STUDY OF SELINEXOR PLUS RUXOLITINIB IN PATIENTS WITH TREATMENT-NAÏVE
MYELOFIBROSIS. HemaSphere, 6(Suppl), pp.895-896. - Dugom, Laura, et al. “Improving Robeson County Public School Curriculum to Create Educational and Health Equity Among Lumbee Tribe: A Pilot Program to Reform Policy.”; (2020)
- Fuentes, Vannessa, and Laura Dugom. “Health Education Oral Session (SA).”APHA’s 2020 VIRTUAL Annual Meeting and Expo (Oct. 24-28). APHA, 2020.
Speaking Engagements/Conference Presentations
- ALS MND Poster Presentation for Target ALS- 2024
- NEALS Poster Presentation for Target ALS- 2024
- American Public Health Association (APHA) Abstract Reviewer for Aging and Public
- Health and Genomics- 2020-2021
- Minority Health Conference Moderator (the largest and longest-running student-led conference in the country, which was founded to raise awareness around health disparities)- 2020
Awards & Recognitions
- President of Beta Beta Beta Biology Honor Society, 2015-2016
- Deborah K. Smith Award and Biology Scholarship, 2016
Professional Affiliations
- Membership in Scientific Organizations: American Public Health Association- 2018-Present
- Leadership Positions: Young Professionals Board, Curamericas Global- 2022-2024
